ProCE Banner Activity

How I Manage Bothersome and Distressing Side Effects from PARP Inhibitors and ADT in Patients with Prostate Cancer

Clinical Thought

In this expert commentary, Sarah Traverso, MMS, PA-C, describes how advance practice providers can help optimize quality of life for patients with metastatic castrate-resistant prostate cancer receiving PARP inhibitor–based therapy.

Released: November 30, 2022

Expiration: November 29, 2023

Begin Activity



Sarah Traverso

Sarah Traverso, MMS, PA-C

Physician Assistant
Division of Genitourinary Oncology
Northwestern Medicine
Chicago, Illinois

Provided by

ProCE Banner


This activity is supported by


Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck Sharp & Dohme Corp

Additional Information

Program Medium

This program has been made available online.